Eli Lilly and Co. is making the most significant industrial private investment in Alabama’s history. Huntsville will become the site of a $6 billion manufacturing facility for the pharmaceutical giant. The announcement is part of its more than $50 billion plan to expand U.S. operations. Construction is expected to start next year and is anticipated to be completed by 2032.

The company selected a 250-acre site in the Greenbrier South section of Huntsville, near Interstate 565 in Limestone County, for a plant that will produce Lilly’s first oral, small molecule GLP-1 receptor agonist. The company is planning to submit orforglipron to global regulatory agencies later this year as an obesity treatment.

The Greenbrier South site will create 450 permanent jobs, including engineers, scientists, operations personnel and lab technicians, and 3,000 construction jobs.

The Greenbrier South site was selected from more than 300 applications, partly due to its proximity to the HudsonAlpha Institute for Biotechnology and the region’s established bioscience infrastructure.